CTT Pharmaceutical 

CTT Pharmaceutical Holdings, Inc. is dedicated to developing innovative oral drug delivery systems, particularly those aimed at pain management and treatment. The company's core expertise lies in rapidly dissolving dosage forms. Central to their technological portfolio are advanced, thin oral wafers designed to be impregnated with natural or synthetic cannabis extracts, presenting an alternative to traditional consumption methods such as smoking or ingestion. Their key proprietary asset is a patented, orally administered wafer, formulated with at least one physiologically acceptable film-forming agent. The entity, formerly known as Mindesta Inc., officially rebranded as CTT Pharmaceutical Holdings, Inc. in July 2015. Its operations are based in Ottawa, Canada.